Radical prostatectomy in the 21st century - The gold standard for localized and locally advanced prostate cancer

Frontiers of Radiation Therapy and Oncology

Volumn 41, Issue , 2008, Pages 7-14

  Schostak, M ^a   Miller, K ^a   Schrader, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; HUMAN; MALE; PROSTATE TUMOR; PROSTATECTOMY; STATISTICS;

HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 49449087260     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000139873     Document Type: Conference Paper

References (46)

1. Bertz J, Hentschel S, Hundsdörfer G, Kaatsch P, Katalinic A, Lehnert M, Schön D, Stegmaier C, Ziegler H: Krebs in Deutschland, 5. überarbeitete, aktualisierte Ausgabe. Saarbrücken, Gesellschaft der epidemiologischen Krebs register in Deutschland e.V. und das RKI, 2006.
2. Billroth T: Carcinoma der Prostata, Chir. Erfahrungen. Arch Klin Chir 1869;10:548.
3. Young HH: The cure of cancer of the prostate by radical perineal prostatectomy (prostate-seminal-vesiculectomy). J Urol 1945;53:188-256.
4. Young HH: The early diagnosis and radical cure of carcinoma of the prostate. Being a study of 40 cases and presentation of a radical operation which was carried out in four cases. 1905. J Urol 2002;167:939-946; discussion 947.
5. Pound CR, Brawer MK, Partin AW: Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. Rev Urol 2001;3:72-84.
6. Lerner SE, Blute ML, Zincke H: Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol 1996;14:12-20; discussion 21.
7. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, Fearn PA, Kattan MW: Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715-717.
8. Karakiewicz PI, Eastham JA, Graefen M, Cagiannos I, Stricker PD, Klein E, Cangiano T, Schroder FH, Scardino PT, Kattan MW: Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5,831 patients. Urology 2005;66:1245-1250.
9. Obek C, Lai S, Sadek S, Civantos F, Soloway MS: Age as a prognostic factor for disease recurrence after radical prostatectomy. Urology 1999;54:533-538.
10. Khan MA, Han M, Partin AW, Epstein JI, Walsh PC: Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology 2003;62:86-91; discussion 91-92.
11. Khan MA, Partin AW, Mangold LA, Epstein JI, Walsh PC: Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology 2003;62:866-871.
12. Freedland SJ, Presti JC Jr, Amling CL, Kane CJ, Aronson WJ, Dorey F, Terris MK: Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology 2003;61:736-741.
13. Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, Grossfeld GD, Carroll PR: Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 2001;166:1322-1327.
14. Graefen M, Noldus J, Pichlmeier U, Haese A, Hammerer P, Fernandez S, Conrad S, Henke R, Huland E, Huland H: Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol 1999;36:21-30.
15. Grossfeld GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC, Carroll PR: Does the completeness of prostate sampling predict outcome for patients undergoing radical prostatectomy? Data from the CAPSURE database. Urology 2000;56:430-435.
16. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 2001;28:555-565.
17. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F: EAU guidelines on prostate cancer. Eur Urol 2005;48:546-551.
18. Catalona WJ, Carvalhal GF, Mager DE, Smith DS: Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999;162:433-438.
19. Graefen M, Walz J, Huland H: Open retropubic nerve-sparing radical prostatectomy. Eur Urol 2006;49:38-48.
20. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843-848.
21. Heidenreich A: Intraoperative frozen section analysis to monitor nerve-sparing radical prostatectomy. Eur Urol 2006;49:948-949.
22. Eichelberg C, Erbersdobler A, Haese A, Schlomm T, Chun FK, Currlin E, Walz J, Steuber T, Graefen M, Huland H: Frozen section for the management of intraoperatively detected palpable tumor lesions during nerve-sparing scheduled radical prostatectomy. Eur Urol 2006;49:1011-1016; discussion 1016-1018.
23. Dubbelman YD, Dohle GR, Schroder FH: Sexual function before and after radical retropubic prostatectomy: a systematic review of prognostic indicators for a successful outcome. Eur Urol 2006;50:711-718; discussion 718-720.
24. Gontero P, Kirby RS: Nerve-sparing radical retropubic prostatectomy: techniques and clinical considerations. Prostate Cancer Prostatic Dis 2005;8:133-139.
25. Gontero P, Kirby R: Proerectile pharmacological prophylaxis following nerve-sparing radical prostatectomy (NSRP). Prostate Cancer Prostatic Dis 2004;7:223-226.
26. Briganti A, Salonia A, Gallina A, Chun FK, Karakiewicz PI, Graefen M, Huland H, Rigatti P, Montorsi F: Management of erectile dysfunction after radical prostatectomy in 2007. World J Urol 2007;25:143-148.
27. Chang SS, Duong DT, Wells N, Cole EE, Smith JA Jr, Cookson MS: Predicting blood loss and transfusion requirements during radical prostatectomy: the significant negative impact of increasing body mass index. J Urol 2004;171:1861-1865.
28. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M: Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003;361:201-205.
29. Schwartz K, Bunner S, Bearer R, Severson RK: Complications from treatment for prostate carcinoma among men in the Detroit area. Cancer 2002;95:82-89.
30. Williams D, McCarthy R: Recombinant activated factor VII and perioperative blood loss. Lancet 2003;361:1745; author reply 1745-1746.
31. Schostak M, Matischak K, Muller M, Schafer M, Schrader M, Christoph F, Miller K: New perioperative management reduces bleeding in radical retropubic prostatectomy. BJU Int 2005;96:316-319.
32. Trabulsi EJ, Guillonneau B: Laparoscopic radical prostatectomy. J Urol 2005;173:1072-1079.
33. Loeb S, Smith ND, Roehl KA, Catalona WJ: Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 2007;69:1170-1175.
34. Hakenberg OW, Frohner M, Wirth MP: Treatment of locally advanced prostate cancer - the case for radical prostatectomy. Urol Int 2006;77:193-199.
35. Glode LM: The case for adjuvant therapy for prostate cancer. J Urol 2006;176:S30-S33.
36. Skinner EC, Glode LM: High-risk localized prostate cancer: primary surgery and adjuvant therapy. Urol Oncol 2003;21:219-227.
37. Bottke D, Wiegel T: Prevention of local recurrence using adjuvant radiotherapy after radical prostatectomy. Indications, results, and side effects (in German). Urologe A 2006;45:1251-1254.
38. Takenaka A, Tewari AK, Leung RA, Bigelow K, El-Tabey N, Murakami G, Fujisawa M: Preservation of the puboprostatic collar and puboperineoplasty for early recovery of urinary continence after robotic prostatectomy: anatomic basis and preliminary outcomes. Eur Urol 2007;51:433-440; discussion 440.
39. Takenaka A, Hara R, Soga H, Murakami G, Fujisawa M: A novel technique for approaching the endopelvic fascia in retropubic radical prostatectomy, based on an anatomical study of fixed and fresh cadavers. BJU Int 2005;95:766-771.
40. D'Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ: Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol 2006;176:S11-S15.
41. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD: Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006, CD006019.
42. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP:4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000;38:706-713.
43. Civantos F, Sadek S, Obek C, Lai S, Soloway M: Neoadjuvant hormonal therapy prior to radical prostatectomy. Mol Urol 1999;3:201-204.
44. Mantz CA, Nautiyal J, Awan A, Kopnick M, Ray P, Kandel G, Niederberger C, Ignacio L, Dawson E, Fields R, et al: Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors. Cancer J Sci Am 1999;5:230-236.
45. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
46. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.